Eli Lilly has agreed to acquire clinical-stage biotech AtaiBeckley in a deal valued at up to $3.8 billion, adding promising therapies for treatment-resistant depression to its neuroscience portfolio. Lilly will pay $6.75 per share upfront, with additional payments tied to clinical and regulatory milestones, representing a 40% premium over recent share prices. AtaiBeckley's lead drug, BPL-003, has shown rapid symptom reduction in trials and received FDA Breakthrough Therapy status, with Phase 3 underway. The acquisition aims to accelerate development of innovative mental health treatments and is expected to close in Q3 2026, pending approvals.
Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, gaining access to experimental drugs targeting mental health conditions like treatment-resistant depression. AtaiBeckley's lead drug, a DMT-based nasal sp...
Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...
